Immunotech Laboratories, Inc. (Immunotech) is a drug development company that focuses on research and development in the biotechnology field. The Company is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - OTC Markets 16:44:35 26/11/2024 GMT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-50.00%	-

22/12/17	Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	CI
22/06/17	Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	CI

Market Cap	6.06M 5.25M 4.96M 4.5M 8.44M 581M 8.49M 59.21M 22.88M 295M 22.75M 22.24M 939M	P/E 2008 *	-	P/E 2009	-310x
Enterprise Value	7.25M 6.28M 5.94M 5.39M 10.1M 695M 10.16M 70.86M 27.38M 353M 27.22M 26.62M 1.12B	EV / Sales 2008 *	-	EV / Sales 2009	-
Free-Float	99.34%	Yield 2008 *	-	Yield 2009	-

22/12/17	Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	CI
22/06/17	Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	CI
13/06/17	Eco-Petroleum Solutions, Inc. acquired Immunotech Laboratories, Inc..	CI
30/09/16	Immunotech Laboratories, Inc. cancelled the transaction announced on October 1, 2013	CI
20/11/14	Ebola becomes latest stock scam, SEC says	RE
21/10/14	Immunotech Laboratories, Inc. and Immunotech Laboratories, BG Enter into Agreement with Uldic Investment to Market Potential Ebola Virus Disease Treatment in Africa	CI
07/10/14	Immunotech Laboratories, Inc and Immunotech Laboratories, BG. Announces Successful Completion of Phase I and Phase II Field Trials of HIV/AIDS and Hepatitis C Virus Treatment	CI
28/08/14	Immunotech Laboratories, Inc. Announces Completion of Phase I and Phase II Field Trials of Patented Treatment of the HIV/AIDS and Hepatitis C Viruses	CI
01/10/13	Immunotech Laboratories, Inc. announced that it expects to receive funding from World Finance Capital Holdings Inc.	CI
15/04/13	Immunotech Laboratories, Inc. Appoints Blaine Nabors as VP of Business Development	CI
01/03/13	Immunotech Laboratories, Inc. Relocates to New Research & Development Laboratory Facility	CI
20/02/13	Immunotech Laboratories, Inc. Announces Clinical Trials Updates for company's AIDS-HIV 'IPF' Medicines	CI
04/02/13	Immunotech Laboratories, Inc. Appoints Valentin Dimitrov to Board of Directors	CI

1 week	-50.00%
Current month	-50.00%
1 month	-50.00%
3 months	-50.00%
6 months	-50.00%

Immunotech Laboratories, Inc. Share Price

Stocks

IMMB

US45254F2039

Biotechnology & Medical Research

Valuation: Immunotech Laboratories, Inc.

Latest news: Immunotech Laboratories, Inc.

Press Releases: Immunotech Laboratories, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Immunotech Laboratories, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	30/06/2014
Valentin Dimitrov BRD	Director/Board Member	61	03/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOTECH LABORATORIES, INC.	-.--%	-50.00%	-.--%	-83.33%	115K
WUXI APPTEC CO., LTD.	+0.66%	+1.83%	+47.32%	+97.63%	69.69B
ARGENX SE	+1.32%	+0.44%	+37.05%	+76.08%	61.24B
INSMED INCORPORATED	+2.22%	-4.83%	-15.32%	+360.65%	26.77B
WUXI BIOLOGICS (CAYMAN) INC.	+0.32%	+5.47%	+27.74%	+14.91%	26.12B
BIONTECH SE	-0.89%	-2.34%	-3.46%	-15.24%	24.07B
GENMAB A/S	+0.86%	+7.06%	+26.06%	-14.33%	20.39B
PHARMAESSENTIA CORPORATION	0.00%	-10.41%	+171.96%	+298.75%	15.72B
EXELIXIS, INC.	-0.21%	-2.66%	+45.07%	+160.34%	14.07B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.17%	-2.74%	-9.79%	+455.90%	14.03B
Average	+0.44%	-1.68%	+32.66%	+135.14%	27.21B
Weighted average by Cap.	+0.69%	-0.95%	+35.02%	+125.68%

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.01
10 years	0		0.09

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-